Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two investor conferences this month. The company has announced that president and CEO Rodney Varner will be presenting to investors at both the 2022 BIO CEO and Investor Conference and at the 2022 Diamond Equity Research Conference; his presentation will include an overview of the company’s gene therapies for cancer and diabetes. The BIO CEO and Investor event is slated for Feb. 14–17, 2022. Varner’s virtual presentation will actually be available on demand beginning Feb. 11, 2022. The one-day Diamond Equity Research Conference will be held Feb. 24, 2022, and Varner is scheduled to present at 3 p.m. EST. At these events, Varner will be available to participate in virtual one-on-one meetings with registered participants or answer questions following the presentation.
To view the full press release, visit https://ibn.fm/oh3FT
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell-signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R) (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.